LONDON, April 02, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation ...

Autolus Therapeutics plc LONDON, April 02, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and ...

Truist lowered the firm’s price target on Autolus Therapeutics (AUTL) to $10 from $11 and keeps a Buy rating on the shares.The firm is updating its model and estimates for Autolus, slightly ...

LONDON, April 02, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation ...

Truist lowered the firm’s price target on Autolus Therapeutics (AUTL) to $10 from $11 and keeps a Buy rating on the shares. The firm is ...

Autolus Therapeutics shares last traded at $1.92, with a volume of 220,321 shares traded. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates ...

Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics Call to Discuss the Full Year 2024 Financial Results and Business Updates. As a reminder, this conference call is being recorded.

Autolus Therapeutics Ltd (AUTL) recently reported its financial results for the fourth quarter of 2024, revealing a net loss of $220.7 million, compared to a $208.4 million loss in the previous year.

Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces its ...

Autolus Therapeutics Ltd (AUTL) recently reported its financial results for the fourth quarter of 2024, revealing a net loss of $220.7 million, compared to a $208.4 million loss in the previous year.

LONDON, March 20, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T ...

Autolus Therapeutics has a 1 year low of $1.68 and a 1 year high of $6.63. A number of brokerages recently issued reports on AUTL. The Goldman Sachs Group raised Autolus Therapeutics from a ...